Pioneers in Rare Disease
Established in 1997, BioMarin is a world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. We take pride in going where the science leads us, pioneering innovative treatments for debilitating and life-threatening conditions where we can significantly improve upon the
Our culture revolves around the ethos that no disease should go untreated, and our people are driven to discover, develop, and commercialise medicines that give patients, their families, and their caregivers hope where there was little or none. We fuel our R&D engine by looking for opportunities that align with our strengths and competencies. And we relentlessly pursue exciting, early-stage science that has the potential to
Our employees feel connected to their work at BioMarin because they believe in our purpose: the patient. The passion and dedication that our employees bring to work each day is a testament to the inspiration our patients provide, and the knowledge of the impact we can
BioMarin at a Glance
-
Headquarters
San Rafael, California
-
Founded
1997
-
President and CEO
Alexander Hardy
-
Employees
~3,000
-
Focus
Rare genetic diseases
-
Therapy Areas
PKU
Types of MPS
CLN2 Disease
Achondroplasia
Haemophilia A -
Research Areas
Skeletal Dysplasias & Growth-Related Conditions
Musculoskeletal & Metabolic Conditions
Access our Ireland gender pay gap reports here.
2024 Report 2024 Report ⌃Our 2023 Report and 2022 Report are also available.
We focus on rare conditions where we believe we can make a meaningful impact.
Learn More about Diseases & Conditions ⌃We take pride in manufacturing complex therapies for the patients who need them most.
Learn More about our manufacturing ⌃
We support programmes and activities that foster excellence in patient care and provide valuable scientific, medical, and educational information.
Learn More Funding & Support ⌃Leadership Team
Our management team represents a dynamic cross section of business, clinical and biotechnical expertise.
Learn More about our leadership team ⌃